To define the basis of the heterogeneity of angiotensinogen, we have characterized (a) the immunoreactivity of high molecular weight (HMW) and low molecular weight (LMW) plasma angiotensinogen, (b) the angiotensinogen precursor synthesized by cell-free translation, and (c) angiotensinogen secreted by human hepatoma (Hep G2) 
Introduction
Angiotensin plays a major role in the control of blood pressure and in fluid and electrolyte homeostasis. The only known precursor of angiotensin is angiotensinogen (renin substrate), a glycoprotein secreted by the liver and also recently shown to be synthesized by the brain (1) . Renin (EC 3.4.99. 19 ) cleaves angiotensinogen at a single site between amino acids 10 and 11 to produce the decapeptide angiotensin I (Al)' and des-Alangiotensinogen (2) (3) (4) (5) . Al is subsequently converted to the biologically active angiotensin II (All) by angiotensin-converting enzyme (dipeptidyl carboxypeptidase, peptidyldipeptide hydrolase; EC 3.4.15.1), which cleaves the carboxyl dipeptide from Al (6) .
Previous studies of plasma angiotensinogen in humans (7-21), hogs (22) , rats (4, (23) (24) (25) , and rabbits (26) have demonstrated that plasma angiotensinogen is heterogeneous with respect to its electrophoretic behavior and behavior on gel and ion-exchange chromatography, and isoelectric focusing. Whereas plasma angiotensinogen has been purified to homogeneity, as demonstrated by N-terminal amino acid determination (4, 5, 22) , each purified fraction has represented only a proportion of the different molecular species present in plasma.
Several studies have suggested that variable glycosylation may be the basis for the heterogeneity of plasma angiotensinogen, and our previous studies (27) have demonstrated that the heterogeneity of rat plasma angiotensinogen can be fully accounted for by variation in N-glycosylation. However, in man, in addition to the predominant form of angiotensinogen (low molecular weight, LMW) with mol wt -60,000, a high molecular weight (HMW) form of plasma angiotensinogen has been identified (7, 8, 11, 12, 17, 18 ). This HMW angiotensinogen has a reduced mobility, compared with LMW angiotensinogen, on nondenaturing polyacrylamide gel electrophoresis (PAGE), and elutes close to the void volume on Sephadex G-200 column chromatography (7, 8) . HMW angiotensinogen is of increased abundance in plasma of pregnant women, women taking oral contraceptives, and patients on glucocorticoid therapy or with advanced essential hypertension or hypertension with uremia (12) . In these studies, angiotensinogen was measured by the amount of Al generated by incubation with renin. Eggena et al. (1 1, 12 ) have reported that a polyclonal antibody raised against LMW angiotensinogen does not recognize HMW angiotensinogen, raising the question whether HMW and LMW angiotensinogen differ in amino acid sequence.
Kageyama et al. (28) have recently cloned and sequenced a cDNA prepared from liver RNA which has provided the primary structure of LMW human angiotensinogen. However, the relationship of the initial translation product to the various forms of secreted angiotensinogen remains to be defined, in particular, whether all forms of angiotensinogen are derived from a single precursor.
In the present study we have examined the bases of the heterogeneity of human plasma angiotensinogen by using several experimental approaches. Our studies were performed using two polyclonal and two monoclonal antibodies raised against pure human LMW angiotensinogen. Initially, we showed that all of these antibodies recognized both HMW and LMW plasma angiotensinogen. We subsequently used these antibodies to characterize the precursor of angiotensinogen synthesized by cell-free translation of RNA prepared from human liver and human hepatoma (Hep G2) cells (29), by using immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). We have compared the angiotensinogen precursor with plasma angiotensinogen and with angiotensinogen secreted by Hep G2 cells. We have characterized the nature of glycosylation of secreted angiotensinogen using (a) tunicamycin to inhibit N-glycosylation, (b) concanavalin A-Sepharose column chromatography, (c) neuraminidase to remove sialic acid residues, and (d) trifluoromethane sulfonic acid to deglycosylate angiotensinogen. Finally, we have studied the effects of dexamethasone and mestranol on these secreted forms of angiotensinogen. (19) .
Plasma was obtained by centrifugation of blood anticoagulated with EDTA, and stored at -300C. Antibodies to human angiotensinogen. The preparation and characterization of polyclonal antibodies raised against pure angiotensinogen have been described previously (21) . Polyclonal antibodies HCI and MAP each had a dissociation constant of -0.5 X 10-" M. The preparation of monoclonal antibodies will be described elsewhere (Bouhnik, J., manuscript in preparation). Monoclonal antibodies F607C l1 and F6lICII had dissociation constants of 0.86 X 10-12 M and 0.85 X 10-" M, respectively. Antibody F60CI1, but not F607Cl 1, recognized angiotensinogen of marmoset (Callithrix jacchus) and baboon (Papio papio). Neither monoclonal antibody recognized angiotensinogen of dog, rat, hog, rabbit or fetal calf, or AI, All, or horse tetradecapeptide.
Measurement of angiotensinogen. Angiotensinogen was measured either by direct radioimmunoassay (RIA) or by RIA of Al generated by incubation with renin sufficient to completely exhaust the angiotensinogen (enzymatic assay), as described elsewhere (21) . The sensitivity of the direct angiotensinogen RIA (polyclonal antibodies) and the Al RIA, i.e., the amount of antigen necessary to obtain a 10% decrease in bound tracer, was 2.5 fmol for each assay. However, because the enzymatic assay of angiotensinogen involved a dilution of at least fivefold during the incubation with renin, the sensitivity of the enzymatic assay of angiotensinogen was approximately one- (32) . RNA was translated using a nuclease-treated rabbit reticulocyte lysate (27) .
Cell antibodies, 10 Ml of PSB were first coated with 1 Ml of rabbit antimouse immunoglobulin (Nordic Immunological Laboratories, Tilburg, The Netherlands), then, after washing, with 1 Ml of monoclonal antibody (hybridoma culture supernatant). Subsequently, immunoprecipitation was performed as previously described for polyclonal antibodies (27) .
The methods used for SDS-PAGE on 9% gels and autoradiography have been described previously (27) . Molecular Kalyan and Bahl (36, 37) , except that in some experiments the reaction was terminated with piperidine instead of pyridine. After dialysis against water, angiotensinogen was immunoprecipitated and subjected to SDS-PAGE (27) .
Statistical methods. Results are expressed as mean± 1 SE. Statistical comparison was either by Student's t test (38) or Mann-Whitney U test (39) .
Results
Recognition of HMW and LMW angiotensinogen by both polyclonal and both monoclonal antibodies. As previously described by Gordon and Sachin (8) , chromatography of plasma on Sephadex G-200 Superfine clearly separated HMW from LMW angiotensinogen: HMW angiotensinogen eluted just after the column void volume and LMW angiotensinogen eluted just before bovine serum albumin. The results obtained for plasma from a woman in the third trimester of pregnancy are shown in Fig. 1 . Column fractions were assayed for angiotensinogen by using both the enzymatic assay and the direct RIA. Whereas there was a good agreement between the enzymatic assay and the direct RIA for LMW angiotensinogen, for HMW angiotensinogen the ratio of values obtained by the direct RIA and the enzymatic assay was 0.26. Moreover, in a series of eight different plasmas from two males, two females with normal menstrual cycles, two females taking oral contraceptives, and two women in the third trimester of pregnancy, the ratio of values obtained by the direct assay and the enzymatic assay was similar (0.25±0.01, mean±SE, n = 8), despite a fivefold variation in concentration of plasma angiotensinogen with varying proportions (2. 50 ,000. After cleavage by renin, the precursor was reduced to mol wt 45,600 (Fig. 3) , representing des-AIangiotensinogen. Both the precursor and des-Al-angiotensinogen were immunoprecipitated by both polyclonal antibodies. However, neither monoclonal antibody immunoprecipitated either form of angiotensinogen (Fig. 3) . Identical results were obtained with RNA prepared from livers of three individuals (all male) and also RNA prepared from Hep G2 cells (data not shown).
Migrating ahead of the angiotensinogen precursor on SDS-PAGE was a protein (mol wt 48,000), which in many experiments (see Fig. 8 ) showed a decreased abundance after incubation with renin. However, this band was considered to be nonspecific since it was also seen, though often in lesser abundance, following immunoprecipitation with nonimmune serum (Fig. 3) . Moreover, this band persisted after preabsorption of antibody HCl with pure angiotensinogen, whereas both the 50,000-mol wt precursor and the 45,600-mol wt renin cleavage product were extinguished by this procedure (data not shown). Other negative controls included the failure to immunoprecipitate the 50,000-mol wt precursor from lysate incubated without Figure 3 . Identification of angiotensinogen precursor synthesized by cell-free translation. Liver RNA was translated using reticulocyte lysate and then incubated for 60 min at 37°C with cycloheximide (10 Mg/ml) in the absence or presence of renin (0.5 Goldblatt U/ml). The cycloheximide was added to prevent further translation (27) . The lysate was then immunoprecipitated and subjected to SDS-PAGE and autoradiography. Fractionation of liver mRNA on an agarose gel showed angiotensinogen mRNA to be -2,000 bases in length (Fig. 4 (Table I) .
Angiotensinogen secreted by Hep G2 cells, either in the absence or presence of tunicamycin, when quantitated by the direct RIA caused a displacement of '251.iodoangiotensinogen which was parallel to that of pure angiotensinogen (Fig. 5 ). There was a good correspondence between the direct RIA and the enzymatic assay (Fig. 6) .
On (Fig. 7) . Preabsorption of antibody with pure angiotensinogen extinguished all forms (data not shown).
All five forms of angiotensinogen secreted by tunicamycintreated Hep G2 cells were cleaved by renin with an equal reduction in molecular weight (Fig. 8) . The predominant 46,200-mol wt form, after cleavage by renin, had an identical mol wt (45, 600) to the des-AI-angiotensinogen resulting from renin cleavage of the precursor synthesized by cell-free translation (Fig. 8) . The reticulocyte lysate does not glycosylate proteins. Thus the 46,200-mol wt angiotensinogen secreted by tunicamycin-treated cells represented nonglycosylated angiotensinogen, whereas the other higher molecular weight forms represented angiotensinogen with some posttranslational modification. That all five forms showed an equal change in molecular weight after cleavage by renin indicated that this posttranslational modification was an increase in molecular weight of the C-terminal portion of the angiotensinogen molecule; there was no evidence that any of the five forms contained an N-terminal extension. The reduction in mol wt of 600 after cleavage by renin was only half the expected change, given the mol wt of Al of 1,297. This probably represents the failure of angiotensinogen and des-AI-angiotensinogen to migrate on SDS-PAGE in a manner identical to the molecular weight standards.
These higher molecular weight forms of angiotensinogen secreted by tunicamycin treated Hep G2 cells did not represent residual N-glycosylation, since tunicamycin concentrations of 1, 5, and 10 ug/ml resulted in identical patterns on SDS-PAGE (Fig. 9) . Although 1 mtg/ml of tunicamycin failed to completely inhibit the incorporation of [3H]glucosamine into angiotensinogen, both 5 and 10 ,ug/ml of tunicamycin completely inhibited N-glycosylation, as shown by immunoprecipitable [3H]glucosamine labeled angiotensinogen (Table I) Chromatography on concanavalin A-Sepharose. Hep G2 cells incubated in the absence of tunicamycin secreted angiotensinogen which was, in part, of higher molecular weight than pure plasma angiotensinogen and '25I-iodoangiotensinogen (Fig.   9 ). This angiotensinogen secreted by Hep G2 cells could be separated into two fractions, one that did not bind and another that did bind to concanavalin A (Fig. 10) . The fraction that did not bind to concanavalin A included the higher molecular weight component of angiotensinogen, whereas the fraction which did bind to concanavalin A had an identical mobility on SDS-PAGE to pure plasma angiotensinogen (Fig. 9 ).
All forms of angiotensinogen secreted by tunicamycintreated Hep G2 cells failed to bind to concanavalin A (Fig. 10) .
Treatment with neuraminidase. For angiotensinogen secreted by Hep G2 cells incubated in the absence of tunicamycin, treatment with neuranminidase caused a considerable reduction in molecular weight, although the extent of heterogeneity was retained (Fig. 11) .
For angiotensinogen secreted by tunicamycin-treated cells, the major effect was a specific extinction of the 49,200-mol wt form (Fig. 11) . The 49,600-mol wt form was not evident in this experiment. However, the predominant 46,200 mol wt, and also the 46,800-and 48, 100-mol wt forms were essentially unaffected by neuraminidase. The bands of mol wt < 46,200 in Fig. 11 indicate proteolysis of angiotensinogen by protease contamination of the neuraminidase preparation.
Deglycosylation with TFMS. For angiotensinogen secreted by Hep G2 cells incubated in the absence of tunicamycin, TFMS produced extensive deglycosylation with marked reduction in both the molecular weight and heterogeneity (Fig. 12) .
For angiotensinogen secreted by tunicamycin-treated Hep G2 cells, TFMS caused an extinction of all of the minor forms, with preservation of the predominant 46,200-mol wt form (Fig. 12 ). Table II . Exposure to tunicamycin (5 ,g/ml) for 20 h had no effect on cell number of confluent cultures and the data for cell number shown in Table II (Table  II, Fig. 13 ). Dexamethasone also produced a 50% increase in net protein synthesis and secretion as shown by TCA-precipi- Table II) .
The smaller increase in angiotensinogen secretion in response to 10-6 M dexamethasone, compared with l0-7 M dexamethasone (Fig. 13) , may be due in part to inhibition of cell growth by the higher concentration of dexamethasone, which was associated with a 25% reduction in cell number (P < 0.01, Table II ).
In the absence of tunicamycin, mestranol (l0-7 and 10-6 M) had no significant effect on either angiotensinogen production or incorporation of radiolabel. However, in the presence of tunicamycin, an increase in angiotensinogen production of 86% for 10-7 M mestranol and 57% for 10-6 M mestranol was observed, which was statistically significant for the lower concentration of mestranol (Fig. 13) . [35S]Methionine-labeled angiotensinogen secreted by Hep G2 cells incubated in the absence or presence of tunicamycin (5 In the present experiments, immunoprecipitation of angiotensinogen secreted by Hep G2 cells by monoclonal antibodies was less than quantitative (Fig. 7) because only small amounts of antibody were available. These monoclonal antibodies have not, as yet, been prepared in large scale. Although recognizing both HMW and LMW plasma angiotensinogen and both glycosylated and nonglycosylated angiotensinogen secreted by Hep G2 cells, these monoclonal antibodies did not recognize either the angiotensinogen precursor synthesized by cell-free translation or des-AI-angiotensinogen resulting from renin cleavage of the precursor (Fig. 3) . In addition, we have shown that these antibodies do not recognize des-AI-angiotensinogen resulting from renin cleavage of either glycosylated or nonglycosylated angiotensinogen secreted by Hep G2 cells (Bouhnik, J., manuscript in preparation). In contrast, both polyclonal antibodies recognized all forms of angiotensinogen including the precursor, and glycosylated and nonglycosylated des-Alangiotensinogen. These data suggest that the monoclonal antibodies recognize the N-terminal region of the angiotensinogen molecule, which may be subject to steric hindrance by the signal peptide, and also to some conformational change following cleavage by renin.
Characterization of plasma angiotensinogen. The studies of Gordon and Sachin (7, 8) However, the validity of the enzymatic assay of HMW angiotensinogen remains to be established. Consequently, any attempt to characterize the kinetics of the renin-HMW angiotensinogen reaction must await such validation. That our recoveries of plasma angiotensinogen from Sephadex G-200 column chromatography were consistently over 100% (see Methods) suggests that some disaggregation of HMW angiotensinogen occurred during chromatography and emphasizes the doubtful validity of the enzymatic assay of HMW angiotensinogen.
Characterization ofprecursor and secreted forms of angiotensinogen. In the present study, the different forms of angiotensinogen secreted by Hep G2 cells have been characterized by several criteria. These include immunoprecipitation by both polyclonal and both monoclonal antibodies (Fig. 7) , mobility on SDS-PAGE, and cleavage by renin. The des-AI-angiotensinogen generated by renin cleavage of the precursor synthesized Human Angiotensinogen 1889 by cell-free translation had a mobility identical to that of des-AI-angiotensinogen produced by renin treatment of nonglycosylated angiotensinogen secreted by tunicamycin-treated Hep G2 cells (Fig. 8) . These results have enabled us to confidently identify both the precursor and secreted forms of angiotensinogen. Angiotensinogen is the only known substrate of renin. Thus, the cleavage by renin of the different forms of angiotensinogen characterized in this study represents a highly specific method for their identification. The relative resistance of the angiotensinogen precursor to cleavage by renin (Fig. 8) was probably due to inhibition of renin by the hemoglobin in the 43 ,000. The autoradiographs show a HMW (>200,000) protein which eluted in all column fractions, though it was most abundant in the column void volume. This protein does not represent angiotensinogen since it was also immunoprecipitated by nonimmune serum, and was not extinguished by preabsorption of the antibody with pure angiotensinogen. This protein showed a decrease in molecular weight when secreted by tunicamycin-treated cells, indicating N-glycosylation, and is considered to be fibronectin, a glycoprotein composed of two similar disulfide-bonded subunits, each with an approximate mol wt of 220,000.
lysate (40), although it is also possible that the signal peptide of the precursor may interfere with the action of renin.
We have previously reported that cell-free translation of rat liver RNA revealed two angiotensinogen precursors (1, 27) . Therefore, to verify our finding of only one angiotensinogen precursor synthesized by cell-free translation of human liver RNA, we fractionated mRNA on an agarose gel in the presence of 12.5 mM methylmercury hydroxide. The results confirmed our finding of only one angiotensinogen precursor (Fig. 4) . The estimated size of angiotensinogen mRNA (2,000 bases; From their analysis of the nucleotide sequence of angiotensinogen mRNA and its corresponding amino acid sequence, Kageyama et al. (28) found the human angiotensinogen precursor to be encoded by two mRNAs which differ only in the length of their 3'-untranslated regions. These authors also found two methionine residues in the putative signal peptide, at positions -24 and -33, and they speculated that both may act as sites of initiation of translation and that the second site (-24) may be predominant. Our evidence for one precursor synthesized by cell-free translation indicates that only one of the two potential initiation sites is used. In the present study, the difference in apparent molecular weight (3,800) between the precursor (50,000) and the mature nonglycosylated angiotensinogen (46, 200) suggests that the signal peptide is 33 rather than 24 amino acids in length, and that the methionine at -33 is the site of initiation of translation. However Glycosylation ofangiotensinogen. The effect of tunicamycin on angiotensinogen secreted by Hep G2 cells indicates that the major posttranslational modification to angiotensinogen is N-glycosylation, which is the major determinant of the heterogeneity of angiotensinogen on SDS-PAGE. Our evidence for N-glycosylation of angiotensinogen is supported by its aminoacid sequence which contains four potential sites of N-glycosylation (28).
As shown in Fig. 9 , angiotensinogen secreted by Hep G2 cells, although similarly heterogeneous on SDS-PAGE, was of higher mean molecular weight than pure plasma angiotensinogen. Concanavalin A-Sepharose chromatography of angiotensinogen secreted by Hep G2 cells (Fig. 10) resolved two components. One component, of molecular weight similar to plasma angiotensinogen (Fig. 9) , bound to concanavalin A, as has been shown previously for plasma angiotensinogen (9, 16) . A second component of higher molecular weight did not bind to concanavalin A, and probably represents angiotensinogen with increased peripheral addition to its oligosaccharide units, of residues with low affinity for concanavalin A, such as sialic acid, galactose and N-acetylgalactosamine (41) (42) (43) . In support of this interpretation, treatment with neuraminidase caused an appreciable reduction in the molecular weight of angiotensinogen (Fig. 1 1) . Plasma angiotensinogen normally contains sialic acid, which contributes to its acidic isoelectric point (15, 20) . However, sialic acid is not a major determinant of the heterogeneity of human angiotensinogen, as determined by SDS-PAGE (Fig. I 1) or isoelectric profile (15) .
In agreement with the present results, we have previously shown that rat hepatoma cells glycosylate angiotensinogen more extensively than rat hepatocytes in primary culture (27) . This may relate to differences in cell growth rate, since a similar growth-dependent alteration in glycosylation mechanisms has been previously reported for other cell systems (44, 45) .
The present studies with tunicamycin demonstrate that Nglycosylation of angiotensinogen is essential neither for its synthesis, processing and secretion, nor its cleavage by renin.
We have previously discussed the possible significance of the inhibition of protein synthesis by tunicamycin (27) . Tunicamycin was also valuable in unmasking a previously unsuspected additional type of posttranslational processing of angiotensinogen. The increase in molecular weight (up to 3,400 from 46,200-49,600) due to this additional posttranslational event suggested 0-glycosylation, and this was confirmed by the specific modification by TFMS of these higher molecular weight forms of angiotensinogen secreted by tunicamycin treated Hep G2 cells (Fig. 12 ). This interpretation is also supported by the results of digestion with neuraminidase ( Fig.  11) and chromatography on concanavalin A (Fig. 10) . The higher molecular weight minor forms of angiotensinogen secreted by tunicamycin-treated cells were specifically modified by neuraminidase, suggesting that they possess sialic acid residues. The failure of these 0-glycosylated forms of angiotensinogen to bind to concanavalin A indicates that they do not contain saccharide residues with affinity for concanavalin A. These data suggest that the 0-linked oligosaccharide units of angiotensinogen may resemble the 0-linked tetrasaccharide units of fetuin, erythrocyte glycophorin and human chorionic gonadotropin (46) (47) (48) . These tetrasaccharide units are composed of a serine-linked N-acetylgalactosamine residue attached to a galactose residue, each of which is attached to a sialic acid residue. Ascertainment whether 0-glycosylation of angiotensinogen is limited to Hep G2 cells or also occurs in vivo, will require appropriate studies of pure plasma angiotensinogen, or studies of human hepatocytes in primary culture.
The effect of TFMS on [35S]methionine-labeled angiotensinogen secreted by Hep G2 cells incubated in the absence of tunicamycin (Fig. 12 ) provided direct support for our studies of the precursor synthesized by cell-free translation, and the effects of tunicamycin on secreted angiotensinogen. It was clearly evident, from the effects of TFMS, that the basis of the heterogeneity of secreted angiotensinogen was variation in glycosylation. In particular, there was no evidence for protein heterogeneity. The failure of TFMS to completely deglycosylate angiotensinogen (Fig. 12) is due to the inability of TFMS to remove asparagine-and serine-linked N-acetylglucosaminyl and N-acetylgalactosaminyl residues. In addition, some galactosyl residues located in serine linked oligosaccharide units may be resistant to removal by TFMS (36, 37) .
As we have previously shown for rat angiotensinogen (27) , renin was able to cleave both the nonglycosylated angiotensinogen precursor synthesized by cell-free translation, and nonglycosylated and O-glycosylated secreted forms of angiotensi-nogen. Further studies will be necessary to define the role of glycosylation in the kinetics of the renin-angiotensinogen reaction, particularly in view of evidence that asparagine at position 14 of angiotensinogen is glycosylated (19) .
Effect of dexamethasone and mestranol. Both glucocorticoids and estrogens increase plasma levels of angiotensinogen and the proportion of which is of high molecular weight (7, 8, 11, 12, 17, 18) . In agreement with our previous study of rat hepatoma cells (33) , dexamethasone caused a several-fold increase in angiotensinogen production by Hep G2 cells. In contrast, mestranol caused a smaller increase in angiotensinogen production which was only evident for tunicamycin-treated Hep G2 cells (Fig. 13) (Fig. 14) .
The design of our present study of steroid effects on angiotensinogen production was based upon our previous study of glucocorticoid stimulation of angiotensinogen production by rat hepatoma cells (33) . In a study of the time course of steroid effect on angiotensinogen production by Hep G2 cells, stimulation by l0-7 M dexamethasone was evident within 24 h but no effect of 10-7 M mestranol was evident at either 24 or 72 h. We have been similarly unable to achieve a stimulation by estrogens of angiotensinogen production by rat hepatoma cells (Coezy, E., unpublished results). Nasjletti and Masson (49) have shown that angiotensinogen production by perfused rat liver increases within 4 h in response to stilbestrol.
Krakoff and Eisenfeld (50) found that the estrogen-induced increase in plasma levels of angiotensinogen in rats was only evident in sexually mature rats, and could be prevented by hypophysectomy. Hep G2 cells are derived from a primary liver carcinoma obtained from a 15-year-old Caucasian boy (51), presumably sexually mature. Thus, the failure of angiotensinogen production by Hep G2 cells to increase in response to mestranol (in the absence of tunicamycin) may represent the absence of some essential pituitary factor, in addition to the possibility of changes in cellular responsiveness accompanying transformation and long-term culture.
Neither (Fig. 14) .
These studies provide direct support for the findings of Tewksbury and Dart ( 17), cited above. Although we have been unable to quantitate the amount of HMW angiotensinogen secreted by Hep G2 cells, the results shown in Fig. 14 do allow us to conclude that HMW angiotensinogen is an aggregate. This conclusion is supported by our studies of the immunoreactivity of HMW angiotensinogen and our characterization of the precursor and secreted forms of angiotensinogen. The HMW angiotensinogen aggregate is dissociable by boiling in SDS and 2-mercaptoethanol, and represents an association either between LMW angiotensinogen molecules or between LMW angiotensinogen and some other protein(s) whose secretion by hepatocytes is stimulated by dexamethasone and mestranol.
